Okay, great. We are going to kick it off. I am Tycho Peterson for the life science team. It is my pleasure to introduce Guardant Health. Welcome. Maybe quick high level, just to recap on the quarter. Obviously, a lot of momentum heading into 2027. Just quick takeaways coming out of 3Q and the messaging for next year.
Yeah, I mean, we continue to, I think, operate at a very high level. It is really nice where you have essentially all our products really sort of hitting their stride. We have Guardant360 continuing to sort of outperform from a late-stage therapy selection point of view. We hit nearly 30% volume growth again. We have our MRD test GuardantReveal growing well over 100% year-over-year, so it is really nice to see that continuing to do very well. Then I think with Shield, seeing that grow, I mean, I think over 300%, or it is 3x in terms of the volumes, and really continue to be one of the fastest diagnostics, one of the most successful diagnostic launches outside of COVID. We couldn't ask for anything more. It has been really great.
Maybe just thinking about Guardant360 , liquid growth, obviously, you have got a decent market. You are getting shares, as you have talked about. Maybe just talk about some of the bigger drivers for next year on Guardant360 .
Yeah, there is a few. We will sort of have the complete launch of Guardant360 Liquid CDx in terms of the FDA-approved version, hopefully next year. That should further catalyze volume growth. We just launched last week another crop of Smart Apps on the platform, 11 new apps, some of them pretty groundbreaking in terms of immune checkpoint inhibitor prediction, being able to sort of characterize PD-L1 in blood. A lot of things we have been working on that took a lot of data analysis and so on to be able to implement and develop and launch, and so that has been exciting. We have the recent sort of approval of ETCAMAH, the SERENA-6 output for breast cancer, that I think will continue to sort of catalyze volume growth next year as more breast cancer patients get tested.
Then, obviously, we'll have probably other Smart App launches next year as well.
I think, yeah, you've talked maybe 30, 40 apps in the pipeline here.
Yeah.
I mean, how quickly do those start to have an impact when you roll them out?
Pretty quickly. It takes some time to sort of educate the market and go through sort of the capabilities and the ins and outs of each of those apps. But if you think about it, these apps become sort of like the next iPhone launch in some ways, where physicians wait for them. They want to see that the test is changing. There's always something new that physicians can look forward to, because fact of the matter is, as good as sort of oncology has gotten from a precision medicine point of view, there was always patients that essentially need more options and need greater utility, and that's what these apps continue to provide.
What is really exciting is that we now have hundreds of thousands of patients that are in the sort of real-world evidence database with EMR data, with claims data. We are really able to develop apps that we could never before, because the ones we are developing need hundreds of thousands of patients with outcome data and so on to actually develop prediction and some of the other biomarker stuff. We are doing things with ADCs and so on. It is really, I would say, the fruition of what we all expected precision medicine to be or precision oncology to be is finally coming to bear.
Just thinking about serialization on liquid and repeat testing, you have obviously got therapy monitoring emerging as a pretty big category. Can you just talk to where you think that is headed?
Yeah. I think one of the things that continues to be underestimated, I think, is how large the market is in therapy selection plus therapy response monitoring. When you think about it, there is close to one million late-stage patients. Many of them will need certainly a tested diagnosis, perhaps two tests, a tissue test and a liquid test. Essentially, those patients want to be sort of monitored in terms of, is this therapy working or not? They may have toxicities with those therapies. The physician may be uncertain whether they need to push through, because the tumor, the cancer is responding. There are a lot of use cases where therapy monitoring really makes a lot of sense. If you think about those one million patients getting multiple therapy monitoring tests, that is millions of tests, sort of testing opportunity in the U.S.
On top of that is the fact that patients should be getting genetic profiling, genomic profiling at every progression. The reason the cancer comes back is because the cancer has changed. It has evolved in terms of its tumor genomic profile, and that is where sort of another Guardant360 can come in and help the physician with hopefully more options for that patient.
Early days on ESR1 with camizestrant, right? FDA approval. Maybe just talk about what you are seeing from physicians so far in terms of repeat serial testing there.
Yeah, it is still early. A lot of patients are just getting their first test in this series, but we are certainly seeing uptick of breast volumes, and I think so far so good in terms of the launch. There is more education required, and we have been coordinating obviously with AZ and with advocacy groups and so on, and are making good progress there.
I guess, historically, there was the tissue-liquid debate, now with tissue submitted to FDA. I guess, how do you think about owning both modalities going forward?
Yeah. We are really excited about the progress we have made with our tissue test. We believe it is now a best-in-class product. It is the one test that essentially covers what I call three legs of the stool, genomics, transcriptomics, and methylation. So it really is a very comprehensive test now. It also fits in line with the challenges of the standard of care. It is able to use a lot less tissue than other tests, and so we have very low QNS rates with that modality. We have seen, I think, the biggest growth, biggest sequential growth we have ever seen in tissue from Q2- Q3, and I think it bodes really well for, I think, increased market share in the coming years, especially when we fully launch Guardant360 Liquid CDx. I think we will be able to catalyze further growth.
The other thing we did was we also submitted for FDA approval for Guardant360 Tissue. We should get that hopefully sometime next year. We think that will also sort of be a growth driver for us.
Attach rate longer term, how do you think about that and the plan?
Yeah, I think the attach rate, a lot of the growth we've seen is counterintuitively has been standalone tissue, which I think is kind of exciting. It shows that the test sort of stands on its own two feet and is something that physicians are sort of coming to and ordering. But as we sort of fully launch the Guardant360 Liquid CDx on the liquid side, then I think there's an opportunity for that attachment rate to go much higher.
We touched on response monitoring earlier. I guess, does this become a distinct market from traditional post-surgical MRD in the long run? Or does the distinction between therapy response monitoring and MRD eventually disappear as clinicians are using Guardant360 Liquid CDx ?
Yeah. If you go really long term, we think the whole market sort of converges where a lot of the drugs that are used in the metastatic setting only sort of become used much earlier. The whole sort of continuum merges into one. But in the short term, the market of therapy response monitoring is really closely linked with therapy selection, and it's why I think we have a sort of prime place in the market, given that we are the leading company in CGP right now.
On Ultra, I know you've launched with pharma, clinical launch by the end of the year. I guess, how do you think about that as replacement upgrade cycle for existing Guardant Reveal volumes versus pushing into kind of newer markets?
Yeah. So we see there's an opportunity where there are qualities that are required for sort of both tests for a subset of patients. When you think about the tissue-free sort of MRD side of the picture, there is a need for speed, for getting results quickly, for getting results without the need for tissue, and for a wider catchment in terms of really detecting tumors that may be different than what was taken out in terms of second primaries or heterogeneity that's there. At the same time, I think there's an opportunity and obviously a market for tumor-informed, especially for ultra-sensitive tests that can go really, really deep.
Yeah, I think we have a plan to basically try to meet the market where it is in terms of making sure that we can essentially hit both sort of use cases and so on with the portfolio that we have between Guardant Reveal and Guardant Reveal Ultra. I would say maybe stay tuned for how we roll that out.
And same answer on data, stay tuned? When will we see? I think we get that a lot.
Oh, the data? No. We are currently running thousands of samples. We have a very, I think, advanced data plan in terms of developing clinical validity studies for all of the major tumor types. And it's something that we're working on, and obviously, as that data is ready, we're very excited to present.
Maybe just shifting over to Shield, 100 million covered lives, 83,000 tests in the third quarter. Just talk a little bit about what's left in terms of sales force expansion, penetrating new physician accounts, and securing additional reimbursement wins. You've got a lot of it, but
Yeah, we are very excited with the performance of the team. We are proud of it, and still we are just scratching the surface. When we are looking at even unscreened patient population, there are 54 million of them, like 17, 18 million annual testing opportunity, and right now, maybe even in terms of run rate in Q3, we are maybe testing a third of a million. Still there is a lot of runway left. In terms of commercial infrastructure, we have still north of 400 people in terms of sales rep, a little bit higher than that, and our steady state number is 600- 700. We are going to continue to scale as we go to 2027. We are expecting a sizable class to start the market early next year.
DTC, our national DTC and influencer strategy, we have been very pleased with some of the pilot results that we got. We launched it late Q1. We measured it really in Q2, and the KPIs are fantastic, and we have a lot of room to flex on investment on the national DTC. As we go to next year, we are expecting to generate more gross profit, and we are going to reinvest some of the additional gross profit into further build-out of sales force and national DTCs. Lastly, maybe I just mentioned this 100 million covered lives. It is really opening up this younger patient population testing for us. Previously, we have been focused on reimbursable cases, and now this reimbursement wins, which came much faster than what we expected, could increase the depth of ordering in the accounts that we are in.
And just, yeah, the mechanics, you got UnitedHealthcare on board, Cigna, Anthem. I mean, just in terms of how that will play out, is it volumes in the first half of the year, ASPs contributing in the second half? Is that the right way to think about it, just in terms of time to contract and
Yeah, maybe I mentioned some words about volume, and then I asked Mike to talk about ASP. United starting in August, Carelon is in effect actually last week, and then the rest would be effective early next year in January. So really, this is a 2027 volume boost story for us. We are very excited about that opportunity. But it is going to take some time for us to build some kind of collection history on the ASP.
Yeah. I mean, just to reemphasize, I think initially we will have the positive coverage. We will start getting paid by these payers. In fact, we have started to see UnitedHealthcare payers now. But when you are out of network, that payment can vary. So, it will take us time to see a consistent history of payment. It will take time to contract with each of these payers. So, yeah, as you mentioned, Tycho, probably back half of 2027, we will start to be able to accrue the revenue on the commercial side, and we will start to see the revenue impact then.
On the margin side, you actually had a nice step down of COGS in 3Q. I know there is still stuff to come on the automation front. Just talk a little bit about the roadmap.
Yeah, the progress we have made on Shield COGS, we are incredibly proud of. When we launched just over two years ago, cost per test was over $1,000. With volume, we have driven that down. Q2, it was just over $400. At the start of Q3, we got this FDA approval for low-cost, high-throughput Shield. That went live in the lab at the start of Q3, and our COGS over that quarter came down from over $400- $330, so a significant step down. As we look forward, we have set this target of $200 cost per test by the end of 2028, so we are well on track for that. Increasing volume is going to continue to help us there. We are also investing heavily in automation. That will need to go through an FDA approval process, and we think that will be sometime late 2027.
When that comes through, obviously we are about to take out a lot of labor costs in the operations, and we will see another nice step down in cost per test. Again, yeah, we are well on track to a $200 cost per test.
I guess just back to the payer dynamic, as we think about commercial ramping, how do you think about the remaining friction around cost sharing, co-pays, remaining out of pocket? How do you think about that?
Right now, what we are seeing actually is vast majority of our patient do not have any kind of financial responsibility. When you are looking at especially preventive services, even sometimes $20, $25 out-of-pocket cost contribution could really impact utilization of that preventative services. We are in a good position, but in order for the rest of the patients to really have access to $0 out-of-pocket, we need to wait for USPSTF guideline inclusion. That would make this really a broad access for everybody.
I guess on that note, what are you expecting? We are supposed to hear something this month on the USPSTF. What is kind of just the latest thinking there?
We are monitoring the situation very closely. The positive thing is some new members have been selected for the first time, actually. I think it is for the first time, really. There are some specialists on the USPSTF panel, like one GI specialist, notably. Based on some of the HHS commentary to media, they supposed to meet in November, and we are monitoring the situation to see if that meeting happens or not. But the role of USPSTF kind of evolved. It used to be the case that really task force recommendation was a gating function for these screening tests. Now, still it is a very important accelerant when you are thinking about $0 out-of-pocket, when you are talking about quality score.
Look, when you are looking at 80% covered lives that we have now, when you are looking at even some state-level legislation, like what has happened in Pennsylvania, that broaden access to Shield blood testing at zero cost to lives over there, we have a lot of business to grow while we are waiting for task force. Still, task force recommendation is an important catalyst.
Yeah, so I guess in terms of the relative importance of USPSTF versus kind of what we saw with Cologuard back in the day, it's just like-
It has changed, yeah.
Yeah. Maybe you could spend a minute on biopharma, some of the initiatives there on the data side.
Yeah, we are going to probably hit something like one exabyte of data in a couple years, so it's an area that we've invested heavily in. The first sort of aspect of that data has been making our tests better. All these apps, going to multi-cancer, multi-disease, and so on, couldn't have been done without having hundreds of thousands of sort of patient data and outcomes. Now we're starting to work with our biopharma partners, and that's been probably the single fastest growing segment of our biopharma and data business, is the work we're doing with biopharma. Obviously, a lot of the work that we're doing outside of that is helping them with their trials, testing patients. A lot of the sort of monitoring of those patients in trial as a sort of surrogate endpoint for those trials has been another area of growth for us as well.
How material could biopharma be over the next couple years?
Yeah, I mean, I think we can continue to grow it pretty nicely. As I said, the data part of it is growing quickly. You're seeing in almost every pharma presentation this early treatment response dynamic where you can test patients in trials at four weeks, eight weeks, 12 weeks, and get an early read in terms of the efficacy of that drug that may predict better than some of the radiographic markers and data in some of those trials. We're seeing that grow very heavily. We're seeing essentially a lot of drugs that don't have traditional genomic biomarkers. We're able to come in with our methylation data, epigenomic data, and help them sort of segment patients much more nicely. So yeah, we see a lot of sort of growth opportunities in the coming years.
We're starting to get more questions beyond oncology as well. Can you talk a little bit about your strategy beyond the oncology portfolio?
Yeah, so I think we are very excited that some of our products, and maybe I give the example of Shield, can detect other diseases beyond oncology. The bridge is really the biomarkers that we are testing, the substrates that we are testing are beyond oncology biomarkers. We have databases just based on the scale of Shield and Guardant Reveal. We have databases at Guardant that for 500 diseases and sub-diseases, we have correlated epigenomic profile in those diseases. We are seeing some genuine, very strong proof of concept about a blood test, same, let's say, Shield blood test, that not only can detect multi-cancer detection, can look at liver disease, can look at kidney disease, can look at other diseases.
The future that we are foreseeing is in few years, when the patient goes for annual checkup or a simple blood test, you can screen that patient for multiple diseases. That's a huge unmet need when we are looking at some diseases with a significant issue in underdiagnosis. This blood test can bring the patient to the journey of multi-disease detection and add significant amount of value.
Mike, one for you on just kind of the free cash flow break-even target. Just thinking about kind of what are the biggest swing factors here between ASPs, COGS we talked about, OpEx.
Yeah, I mean, firstly, from a free cash flow perspective, we've been targeting Q4 of 2027 as the break-even target. We remain well on track for that. I think if you look at the business excluding screening, that became break-even last year. It's positive cash flow this year. It's going to be incremental positive cash flow in 2027. Screening, we've been investing heavily on the sales and marketing side for the last couple of years. That will continue into 2027, but sometime in 2027, we'll reach a certain level of scale where incremental gross profit that we've been reinvesting back into the business is going to start to drop down to the bottom line. We're going to start to get leverage on the screening side of the business.
Yeah, we look at 2027 for screening as starting to sort of reduce the cash burn in the second half of the year. That's going to get us to free cash flow break-even in Q4. The biggest upside we have to that is ADLT for Guardant360. When we set that target, we didn't include ADLT assumption. I think when that comes, it's just going to give us even more confidence that we get there Q4, potentially earlier.
I know you've put out the first half of next year target for ADLT. I mean, is there any risk it could slip, or how do you think about it?
No, we don't believe there's any risk it could slip. It's a relatively simple application. I think our sort of base case is April 1st. That's based on what we saw with Shield. Shield got an FDA approval in August, then the ADLT went into effect April 1st the following year. With Guardant360, we got the FDA approval in July, so we think a similar timeline.
Just thinking about channel a little bit, I mean, you have the Quest partnership, so you've also partnered up in some cases as we think about non-oncology applications. I mean, how do you think about channel needs there? Maybe just talk a little bit about OpEx investments in the channel. Yeah.
We believe once we have a scaled PCP channel, that's highly leverageable. Bunch of testing opportunities that we are looking at and we are prioritizing are going to be toward PCPs. So we are very excited about that opportunity. Again, this is kind of research on pipeline. It's not a very near-term commercial opportunity, but we are excited with what we see.
The returns on the DTC you are spending now, have those been in line with what you have envisioned?
Actually, it was better than what we thought. A good fraction of the cases, based on some of the market research that we have done, we look at the whole funnel, top of the funnel from impression website all the way to bottom of the funnel, that what fraction of Shield orders are consumer-initiated. A material fraction are consumer-initiated with some of the early innings and early investments that we have done on DTC. That is why we are going to scale it as we go to 2027.